Compounds, compositions, and methods for treating T-cell acute lymphoblastic leukemia

Patent metadata

Field	Value
Publication number	US-11459306-B2
Application number	US-201816633074-A
Country	US
Kind code	B2
Filing date	Jul 31, 2018
Priority date	Jul 31, 2017
Publication date	Oct 4, 2022
Grant date	Oct 4, 2022

Abstract

In an aspect, the disclosure provides for compounds (II), compositions, and methods of administering the compounds and compositions to a patient in need thereof. In another aspect, the disclosure relates to compounds and compositions for treating cancer, for example, lymphoid leukemia. The disclosure further provides for compounds which inhibit two phosphoinositide 3-kinase (PI3K) isoforms, y and δ, pharmaceutical compositions comprising said compounds, and methods of using said compounds and pharmaceutical compositions for treatment, amelioration, and/or prevention of non-Hodgkin lymphoma.

First claim

The invention claimed is:

1. A compound of the following formula or salt thereof:

2. The compound according to claim 1 , wherein the compound is:

or a salt thereof.

3. The compound according to claim 1 , wherein the compound is an inhibitor of both PI3Kδ and PI3Kγ.

4. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

5. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.

6. The compound according to claim 1 , wherein the compound is in the form of a pharmaceutical composition, wherein the compound is a dual inhibitor of PI3Kδ and PI3Kγ.

7. A method for treating a non-Hodgkin's lymphoma comprising administering an effective amount of a compound of claim 1 to a subject in need thereof.

8. The method according to claim 7 , wherein the non-Hodgkin's lymphoma is a T-cell lymphoma.

9. The method according to claim 8 , wherein the T-cell lymphoma is peripheral T-cell lymphoma.

10. The method according to claim 7 , further comprising co-administering to the subject at least one chemotherapeutic agent.

11. The method according to claim 10 , wherein the chemotherapeutic agent is actinomycin, amsacrine, anthracycline, busulfan, cisplatin, cytoxan, epirubicin, hexamethylmelamineoxaliplatin, iphosphamide, mitoxantrone, teniposide, triethylenethiophosphoramide, hydrocortisone, cortisone, methylprednisolone, prednisolone, dexamethasone, prednisone, betamethasone, triamcinolone, beclometasone, fludrocortisone, deoxycorticosterone, aldosterone, oxaliplatin, zoledronic acid, ibandronate, verapamil, podophyllotoxin, carboplatin, procarbazine, mechlorethamine, cyclophosphamide, camptothecin, ifosfamide, melphalan, chlorambucil, bisulfan, nitrosourea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP16), tamoxifen, transplatinum, 5-fluorouracil, vincristin, vinblastin, methotrexate, L-asparaginase, rapamycin, dibenzazepine (DBZ), uramustine, carmustine, lomustine, streptozocin, temozolomide, idarubicin, topotecan, pemetrexed, 6-mercaptopurine, darcarbazine, fludarabine, arabinosycytosine, arabinosylcytosine, capecitabine, gemcitabine, decitabine, vinca alkaloids, paclitaxel (TAXOL®), docetaxel (TAXOTERE®), ixabepilone (IXEMPRA®), or combinations thereof.

12. The method according to claim 11 , wherein the chemotherapeutic agent is a glucocorticoid selected from the group consisting of hydrocortisone, cortisone, methylprednisolone, prednisolone, dexamethasone, prednisone, betamethasone, triamcinolone, beclometasone, fludrocortisones, deoxycorticosterone, aldosterone, and combinations thereof.

13. The method according to claim 12 , wherein the chemotherapeutic agent is dexamethasone.

14. The method according to claim 7 , wherein the compound is in the form of a pharmaceutical composition comprising an effective amount of the compound and a pharmaceutically acceptable carrier.

15. The method according to claim 14 , wherein the composition is in a unit dosage form.

16. A method of treating a lymphoma or leukemia comprising administering an effective amount of a compound of claim 1 to a subject in need thereof.

17. The method of claim 16 , wherein the lymphoma or leukemia is acute lymphoblastic leukemia (ALL), T cell acute lymphoblastic leukemia (T-ALL), B cell acute lymphoblastic leukemia (B-ALL), T cell lymphoma, peripheral T cell lymphoma (PTCL), cutaneous T cell lymphoma (CTCL), B cell lymphoma, follicular lymphoma, cutaneous B cell lymphoma, or chronic lymphocytic leukemia (CLL).

18. The method of claim 16 , wherein the lymphoma or leukemia is T-ALL.

19. A method for treating a non-Hodgkin's lymphoma comprising administering an effective amount of a compound of claim 2 to a subject in need thereof.

20. The method according to claim 19 , wherein the non-Hodgkin's lymphoma is a T-cell lymphoma.

21. The method according to claim 20 , wherein the T-cell lymphoma is peripheral T-cell lymphoma.

22. The method according to claim 19 , further comprising co-administering to the subject at least one chemotherapeutic agent.

23. The method according to claim 22 , wherein the chemotherapeutic agent is actinomycin, amsacrine, anthracycline, busulfan, cisplatin, cytoxan, epirubicin, hexamethylmelamineoxaliplatin, iphosphamide, mitoxantrone, teniposide, triethylenethiophosphoramide, hydrocortisone, cortisone, methylprednisolone, prednisolone, dexamethasone, prednisone, betamethasone, triamcinolone, beclometasone, fludrocortisone, deoxycorticosterone, aldosterone, oxaliplatin, zoledronic acid, ibandronate, verapamil, podophyllotoxin, carboplatin, procarbazine, mechlorethamine, cyclophosphamide, camptothecin, ifosfamide, melphalan, chlorambucil, bisulfan, nitrosourea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP16), tamoxifen, transplatinum, 5-fluorouracil, vincristin, vinblastin, methotrexate, L-asparaginase, rapamycin, dibenzazepine (DBZ), uramustine, carmustine, lomustine, streptozocin, temozolomide, idarubicin, topotecan, pemetrexed, 6-mercaptopurine, darcarbazine, fludarabine, arabinosycytosine, arabinosylcytosine, capecitabine, gemcitabine, decitabine, vinca alkaloids, paclitaxel (TAXOL®), docetaxel (TAXOTERE®), ixabepilone (IXEMPRA®), or combinations thereof.

24. The method according to claim 23 , wherein the chemotherapeutic agent is a glucocorticoid selected from the group consisting of hydrocortisone, cortisone, methylprednisolone, prednisolone, dexamethasone, prednisone, betamethasone, triamcinolone, beclometasone, fludrocortisones, deoxycorticosterone, aldosterone, and combinations thereof.

25. The method according to claim 24 , wherein the chemotherapeutic agent is dexamethasone.

26. A method of treating a lymphoma or leukemia comprising administering an effective amount of a compound of claim 2 to a subject in need thereof.

27. The method of claim 26 , wherein the lymphoma or leukemia is acute lymphoblastic leukemia (ALL), T cell acute lymphoblastic leukemia (T-ALL), B cell acute lymphoblastic leukemia (B-ALL), T cell lymphoma, peripheral T cell lymphoma (PTCL), cutaneous T cell lymphoma (CTCL), B cell lymphoma, follicular lymphoma, cutaneous B cell lymphoma, or chronic lymphocytic leukemia (CLL).

28. The method of claim 26 , wherein the lymphoma or leukemia is T-ALL.

Assignees

• Univ Columbia

Inventors

• Landry Donald W
• Deng Shi-Xian
• Xu Xiaoming
• Diacovo Thomas

Classifications

• C07D403/14

  containing three or more hetero rings · CPC title

• C07D473/16

  two nitrogen atoms · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07D401/12

  linked by a chain containing hetero atoms as chain links · CPC title

• A61P35/02

  specific for leukemia · CPC title